DNA test accurately diagnoses rare diseases

Article

Advanced DNA testing for congenital cataracts can quickly and accurately diagnose a number of rare diseases marked by childhood blindness, according to a study recently published online.

Advanced DNA testing for congenital cataracts can quickly and accurately diagnose a number of rare diseases marked by childhood blindness, according to a study published online in Ophthalmology.

Researchers at the University of Manchester, UK, used a DNA sequencing technology called targeted next-generation sequencing on 36 individuals diagnosed with bilateral congenital cataracts. Using a single diagnostic test, the researchers checked for mutations in the 115 genes known to be associated with congenital cataracts.

In 75% of the individuals tested, the DNA test determined the exact genetic cause of the congenital cataracts based on the mutations.

DNA testing one gene at a time would have taken years to complete; the researchers in this study sped up diagnosis to a matter of weeks by testing for mutations in all 115 known congenital cataract genes at one time. The results hold promise for faster and less costly diagnoses, earlier treatment and genetic counselling for affected families.

"There are many diseases that involve congenital cataracts, but finding the exact reason was always difficult," said Graeme Black, DPhil, professor of genetics and ophthalmology at the University of Manchester, and strategic director of the Manchester Centre for Genomic Medicine. "Even with a family history, diagnosing these rare diseases was always a bit of a shot in the dark."

To read an abstract of the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.